Drug Development Pharma - September 4, 2013
Shire extends partnership with Santaris Pharma
The two companies extend their existing partnership in rare genetic disease space. The Danish clinical stage biopharmaceutical company Santaris Pharma focuses on the discovery and development of RNA-targeted therapies. Under the terms of agreement, Shire will have the right to nominate additional collaboration targets for drug discovery and development and Santaris will receive an upfront […]
Drug Development Pharma - August 29, 2013
Cytomed opens pharmaceutical factory in Finland
The Russian-owned company Cytomed has been granted an operating license by the Finnish Medicines Agency Fimea for its pharmaceutical factory located near the border with Russia in Lappeenranta, eastern Finland. Cytomed, founded in 1989 as one of Russia’s first private pharmaceutical manufacturing company, will be testing its equipment and validating its processes during the next […]
Drug Development Pharma - August 6, 2013
Green light for diabetes treatment
The European Medicines Agency, EMA, has concluded that GLP-1 based treatments do not pose new safety concerns for patients with type 2 diabetes. Earlier this year, a study was published that indicated that drugs based on GLP-1 increase the risk of developing pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia. GLP-1, glucagon-like-peptide-1, is a […]
Drug Development Pharma - March 27, 2013
AstraZeneca keeps R&D in Mölndal
AstraZeneca’s site in Mölndal will continue to be a global center for research and development, the company recently announced. At the same time, another 2 300 employees are being made redundant. The company plans to invest in strategic R&D centers in the UK, the US and Mölndal, Sweden, focusing on small molecule and biologics R&D […]
Drug Development Pharma - March 27, 2013
Orion Corporation and Gedeon Richter in new agreement
Orion Corporation and Gedeon Richter Plc. have entered into a long term collaboration agreement for the discovery and development of new chemical entities in the field of cognitive disorders. According to the agreement the partnership provides an opportunity whereby the two companies jointly select and bring forward three discovery phase candidates and share all the […]
Drug Development Pharma - March 21, 2013
A pipeline push from a public-private partnership
A multimillion-euro partnership between industry and the European Union promotes research and communication on developing new antibiotics.
